Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype
复制标题
DOI：
10.1183/13993003.02503-2016
复制
发表时间：
2017-09-01
影响因子：
24.3
通讯作者：
Kwon, O. Jung
中科院分区：
文献类型：
--
作者：
Koh, Won-Jung;Moon, Seong Mi;Kwon, O. Jung
鸟分枝杆菌复合体（MAC）肺病的临床表型对治疗结果和治疗结束后非结核分枝杆菌（NTM）肺病再发的影响尚未有系统的研究。我们评估了481例未经治疗的MAC肺病患者，他们接受了抗生素治疗。2002年1月至2013年12月的12个月。在481例患者中，278例（58%）患有非空洞性结节性支气管扩张（NB）疾病，80例（17%）患有空洞性NB疾病，123例（25%）患有纤维空洞疾病。非空腔疾病患者的有利结果（88%）高于空腔疾病患者(纤维空腔疾病76%，空腔NB疾病78%
The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-naive patients with MAC lung disease who underwent antibiotic treatment for. 12 months between January 2002 and December 2013.Out of 481 patients, 278 (58%) had noncavitary nodular bronchiectatic (NB) disease, 80 (17%) had cavitary NB disease and 123 (25%) had fibrocavitary disease. Favourable outcome was higher in patients with noncavitary disease (88%) than in patients with cavitary disease (76% for fibrocavitary and 78% for cavitary NB disease; p